絞り込み

16640

広告

A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes.

著者 Jax T , Stirban A , Terjung A , Esmaeili H , Berk A , Thiemann S , Chilton R , von Eynatten M , Marx N
Cardiovasc Diabetol.2017 Jan 21 ; 16(1):13.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (23view , 0users)

Full Text Sources

Medical

Miscellaneous

Studies of dipeptidyl peptidase (DPP)-4 inhibitors report heterogeneous effects on endothelial function in patients with type 2 diabetes (T2D). This study assessed the effects of the DPP-4 inhibitor linagliptin versus the sulphonylurea glimepiride and placebo on measures of macro- and microvascular endothelial function in patients with T2D who represented a primary cardiovascular disease prevention population.
PMID: 28109295 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード